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in the Development of Health Economics and Health
Technology Assessment in HungaryWe read with great pleasure ISPOR’s new journal, Value in Health
Regional Issues, which had been devoted to the regions of Central
and Eastern Europe, Western Asia, and Africa (CEEWAA) [1]. We
do believe that ISPOR’s strategic decision on releasing this journal
and providing space for scholars from less developed regions of
the world for publishing their ﬁndings in the ﬁeld of health
economics and outcomes research is an excellent way for
disseminating scientiﬁc outputs throughout these regions.
The ﬁrst CEEWAA issue of Value in Health Regional Issues
provided a well-balanced overview of current research trends,
capacity building, and health policy aspects of countries of the
CEEWAA region. Kaló et al. [2] gave an excellent overview on the
capacity building for health technology assessment (HTA) imple-
mentation in middle-income countries describing the case of
Hungary. Our aim is to give a short overview on the role of the
National Health Insurance Fund Administration (Országos Egész-
ségbiztosítási Pénztár [OEP]) in the development of health eco-
nomics and HTA in Hungary. A more detailed description of the
Hungarian health care system can be found elsewhere [3–10].
The introduction of health economics and HTA into decision
making started in Hungary in to 2001 when a nationwide public
health program was developed. An important part of that com-
plex public health initiative was the introduction of organized,
nationwide cancer-screening programs for breast and cervical
cancer. To explore the cost and beneﬁts of such programs, a
primary health economics analysis was performed by the work-
ing group of the National Health Insurance Fund Administration
(OEP), the only health care ﬁnancing agency in Hungary [11,12].
The cost-effectiveness analysis of breast cancer [13] and cervical
cancer [14] found that both programs are cost-effective in
Hungary from a purchaser’s point of view. After the evaluation
of medical and economic considerations, an organized, nation-
wide breast and cervical cancer screening program was intro-
duced in Hungary in 2002 and 2003, respectively [15,16].
These screening programs represent the ﬁrst case in Hungary
when the health care ﬁnancing authority (OEP) performed a
formal health-economics analysis for the assessment of costs
and beneﬁts of a new medical technology and the results of cost-
effectiveness analysis were considered during the decision-
making process. After the introduction of the screening program,
a monitoring process has been developed for continuous evalua-
tion of the implementation of the program. The results of the
monitoring process have also been published in international
scientiﬁc literature and presented at ISPOR congresses [17–20].ial support: The author has no other ﬁnancial relaThe cost-effectiveness of colorectal cancer screening was also
evaluated by the National Health Insurance Fund Administration
(OEP): simultaneous application of both the guaiac-based test and
the immunochemical fecal occult blood test detecting hemoglo-
bin and albumin was compared with the no-screening strategy
[21]. Colorectal cancer screening proved to be cost-effective in the
Hungarian setting [22]. A small area pilot colorectal cancer
screening project was introduced in the town of Ajka and
surroundings in 2003 to 2004, and further monitoring was also
conducted, but a nationwide colorectal screening program was
still not introduced in Hungary [23–25].
Another important research topic of the Hungarian OEP is the
analysis of hip fractures, including its epidemiology [26–28],
burden of disease [29–32], outcomes research [33,34], and evalua-
tion of biological therapies [35].
The OEP signiﬁcantly contributed to the adoption of the
directive 89/105/EEC of the Council of the European Communities
on transparency in Hungary [36]. The OEP was also a facilitator
for the development of guidelines for conducting economic
evaluation of health care interventions in Hungary [37]. Two
former board members of the National Health Insurance Fund
Administration (OEP) played an important role in the develop-
ment of health economics in Hungary: Csaba Dózsa, former
deputy director general, and Imre Boncz, former department
head. Both were the presidents of ISPOR Hungary Chapter. Andor
Sebestyén, regional director of OEP, and his colleagues won the
best poster presentation award at ISPOR’s Berlin congress in 2012
[38].
Hungarian researchers at universities and research institutes
also prefer to conduct a detailed analysis of the nationwide data
set of the National Health Insurance Fund Administration. Their
research area covers pharmaceutical market analysis [39,40],
cost-of- illness studies [41,42], and epidemiology [43,44].
In conclusion, we can emphasize that Hungarian National
Health Insurance Fund Administration (OEP) had a signiﬁcant
contribution to the development of health economics and HTA in
Hungary through the commitment of its staff members and
leaders, by performing the ﬁrst governmental health-economics
evaluations in Hungary, to incorporate cost-effectiveness results
into the decision-making process of new medical technologies.
I am convinced that ISPOR’s new journal, Value in Health
Regional Issues, will serve as a special forum for researchers from
the CEEWAA region to increase their activity in scientiﬁc
publications.tionships to disclose.
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